News
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors.
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
– Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced the appointment of Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development.
Thermosome Establishes High-Profile Clinical Advisory Board
– Leveraging the transformative potential of TSL-based tumor targeting
– Supporting the progress of Thermosome’s clinical candidate THE001
Thermosome, a drug development company specializing in targeted tumor therapies, today announced the formation of a Clinical Advisory Board to support the advancement of its lead compound THE001 through clinical development.
The board consists of leading international cancer specialists in the fields of soft tissue sarcoma and bladder cancer, experts in hyperthermia, immunotherapy, and surgery/neoadjuvant therapy: Read more…
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
— Key milestone for novel, resorbable breast / pectus reconstruction implants
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today reported encouraging one-year follow-up data of its breast and pectus excavatum scaffolds.
Both pectus and breast implants demonstrated a very good safety profile, were very well accepted by the surgeons and patients expressed high satisfaction and reported an improvement in quality of life. A significant improvement in pain scores was observed in breast reconstruction patients with prior silicone implants. All patients´ breasts maintained their shape and volume after surgery. Read more…